Search research articles
Contact Us
Filters
Showing results (521-530 of 575) with videos related to
Page
of 58
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 5, 2017
Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
Andrea B Apolo, Jeffrey R Infante, Ani Balmanoukian, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
October 21, 2017
Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer
Kyle Wang, Kevin A Pearlstein, Nicholas D Patchett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 6, 2020
Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of <i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403
Sarah B Goldberg, Mary W Redman, Rogerio Lilenbaum, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 13, 2018
Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers
Solange Peters, Rolf Stahel, Lukas Bubendorf, et al.
Research Square
|
July 3, 2026
Alirocumab Plus Cemiplimab in Immunorefractory NSCLC: A Single Arm Phase 2 Study
Eziafa Oduah, Jhanelle Gray, Thomas Stinchcombe, et al.
JAMA Oncology
|
August 1, 2024
Recurrence of Non-Small Cell Lung Cancer With Visceral Pleural Invasion: A Secondary Analysis of a Randomized Clinical Trial
Nasser Altorki, Xiaofei Wang, Bryce Damman, et al.
Nature Communications
|
January 3, 2025
Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial
Jeffrey M Clarke, George R Simon, Hirva Mamdani, et al.
Clinical Pharmacology and Therapeutics
|
May 1, 2014
Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses
M A Phelps, T E Stinchcombe, J S Blachly, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 22, 2021
Coronary Artery Calcifications and Cardiac Risk After Radiation Therapy for Stage III Lung Cancer
Kyle Wang, Hayley E Malkin, Nicholas D Patchett, et al.
JAMA Oncology
|
March 17, 2022
Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216)
Kenneth L Kehl, David Zahrieh, Ping Yang, et al.
Page
of 58
Search research articles
Search
Showing results (521-530 of 575) with videos related to
Sort By:
Page
of 58
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 5, 2017
Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
Andrea B Apolo, Jeffrey R Infante, Ani Balmanoukian, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
October 21, 2017
Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer
Kyle Wang, Kevin A Pearlstein, Nicholas D Patchett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 6, 2020
Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of <i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403
Sarah B Goldberg, Mary W Redman, Rogerio Lilenbaum, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 13, 2018
Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers
Solange Peters, Rolf Stahel, Lukas Bubendorf, et al.
Research Square
|
July 3, 2026
Alirocumab Plus Cemiplimab in Immunorefractory NSCLC: A Single Arm Phase 2 Study
Eziafa Oduah, Jhanelle Gray, Thomas Stinchcombe, et al.
JAMA Oncology
|
August 1, 2024
Recurrence of Non-Small Cell Lung Cancer With Visceral Pleural Invasion: A Secondary Analysis of a Randomized Clinical Trial
Nasser Altorki, Xiaofei Wang, Bryce Damman, et al.
Nature Communications
|
January 3, 2025
Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial
Jeffrey M Clarke, George R Simon, Hirva Mamdani, et al.
Clinical Pharmacology and Therapeutics
|
May 1, 2014
Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses
M A Phelps, T E Stinchcombe, J S Blachly, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 22, 2021
Coronary Artery Calcifications and Cardiac Risk After Radiation Therapy for Stage III Lung Cancer
Kyle Wang, Hayley E Malkin, Nicholas D Patchett, et al.
JAMA Oncology
|
March 17, 2022
Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216)
Kenneth L Kehl, David Zahrieh, Ping Yang, et al.
Page
of 58